Farmers Trust Co. trimmed its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 1.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,138 shares of the biopharmaceutical company’s stock after selling 180 shares during the quarter. Farmers Trust Co.’s holdings in Bristol-Myers Squibb were worth $509,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Welch Investments LLC boosted its holdings in Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 79 shares in the last quarter. Crestwood Advisors Group LLC bought a new stake in Bristol-Myers Squibb in the first quarter worth $116,000. Blue Chip Partners Inc. boosted its holdings in Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 17 shares in the last quarter. American National Bank boosted its holdings in Bristol-Myers Squibb by 11.7% in the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 225 shares in the last quarter. Finally, Proficio Capital Partners LLC boosted its holdings in Bristol-Myers Squibb by 29.6% in the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 504 shares in the last quarter. 68.88% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have commented on the company. Cowen and Company reissued a “hold” rating and issued a $65.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday. BidaskClub raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 price target on the stock in a report on Thursday, August 17th. Finally, William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a report on Monday, June 26th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $62.66.

Bristol-Myers Squibb Company (NYSE:BMY) traded up 0.38% during mid-day trading on Tuesday, hitting $62.94. The company had a trading volume of 2,061,013 shares. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $63.47. The firm has a market capitalization of $103.22 billion, a P/E ratio of 22.99 and a beta of 1.18. The company has a 50-day moving average price of $58.77 and a 200 day moving average price of $55.98.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the previous year, the business earned $0.69 EPS. Bristol-Myers Squibb’s revenue for the quarter was up 5.6% compared to the same quarter last year. Equities analysts forecast that Bristol-Myers Squibb Company will post $2.98 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.49%. Bristol-Myers Squibb’s dividend payout ratio is presently 56.73%.

In other news, Director Theodore R. Samuels II acquired 6,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The stock was bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the purchase, the director now owns 18,000 shares in the company, valued at $1,006,920. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The disclosure for this sale can be found here. 0.23% of the stock is owned by insiders.

WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/09/19/farmers-trust-co-has-509000-holdings-in-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.